Opinion

Video

The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
5 experts are featured in this series
2 experts in this video
2 experts in this video
5 experts are featured in this series
1 expert is featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo